Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × inavolisib × Clear all

Phase

Status

Recruiting 7 Not yet recruiting 2 Withdrawn 1 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 138 Docetaxel 130 Bevacizumab 127 Carboplatin 126 pembrolizumab 124 Gemcitabine 116 Radiotherapy 115 Cisplatin 115 Paclitaxel 112 Capecitabine 101 Rituximab 99 Fluorouracil 93 Oxaliplatin 88 Nivolumab 76 Irinotecan 76 Leucovorin 74 Doxorubicin 71 Dexamethasone 68 Pemetrexed 66 fludarabine 61 Etoposide 60 Bortezomib 57 fludarabine phosphate 56 Erlotinib Hydrochloride 55 Methotrexate 52 Cytarabine 52 Cetuximab 52 Trastuzumab 48 Sorafenib 43 Lenalidomide 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04849364 2025-05-31

PERSEVERE

Hoosier Cancer Research Network

Phase 2 Terminated

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡